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Abstract
Rationale: Whether selective serotonin reuptake inhibitors (SSRIs) exposure during adolescent brain development
causes lasting effects remains unresolved.
Objective: Assess the effects of fluoxetine and paroxetine 60 days after adolescent exposure compared with when
on-drug.
Methods: Male Sprague-Dawley littermates (41 litters) were gavaged on postnatal days 33-53 with fluoxetine (3 or
10 mg/kg/day), paroxetine (3, 10 or, 17 mg/kg/day), or water; half were tested while on-drug (21 litters) and half
after 60 days off-drug (20 litters).
Results: The highest dose of the drugs reduced body weight gain during treatment that rebounded 1 week post-
treatment. On-drug, no significant group differences were found on elevated plus maze time-in-open, zone entries,
or latency to first open entry; however, the high dose of paroxetine significantly reduced head-dips (N = 20/
group). No significant effects were found on-drug for acoustic startle response/prepulse inhibition (ASR/PPI)
although a trend (p < 0.10) was seen, which after combining dose levels, showed a significant increase in ASR
amplitude for both fluoxetine and paroxetine (N = 20-21/group). No differences on immobility time were seen in
the Porsolt forced swim test or in plasma corticosterone at the end of forced swim (N-19-21/group). Off-drug, no
effects were seen in the elevated plus maze (N = 16/group), ASR/PPI (N = 20/group), forced swim (N = 19-20/
group), or plasma corticosterone (N = 19/group). At the doses tested, fluoxetine and paroxetine induced minor
effects with drug on-board but no residual, long-term adverse effects in rats 60 days after drug discontinuation.
Conclusions: The data provide no evidence that fluoxetine or paroxetine have long-term adverse effects on the
behaviors measured here after adolescent to young adult exposure.
Keywords: fluoxetine, paroxetine, acoustic startle response, elevated plus maze, forced swim test, corticosterone,
adolescent brain development
Background
Selective serotonin reuptake inhibitors (SSRIs) are
widely used antidepressants that inhibit the reuptake of
serotonin (5-HT) into the presynaptic terminal by bind-
ing to the serotonin transporter (SERT). SSRIs have
been used with success in adults for treatment of
depression, premenstrual syndrome, obsessive compul-
sive behavior, panic disorder, generalized anxiety disor-
der, social anxiety disorder, and post-traumatic stress
disorder [1-3]. A meta-analysis of adult trials indicates
that suicidality may be increased shortly after antide-
pressant treatment is begun regardless of whether the
drug is an SSRI or tricyclic antidepressant [4].
SSRIs have also been used in children and adolescents,
primarily for depression [5]. It has been suggested that
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children and adolescents may be at higher risk of
adverse effects perhaps because SSRIs are contraindi-
cated for some types of depression (such as bipolar dis-
order) that are often unrecognized in younger patients
[5]. A recent meta-analysis of randomized controlled
trials of SSRI treatment for depression in children and
adolescents found benefit from SSRI treatment, but not
all SSRIs were equally effective. Fluoxetine, sertraline,
and citalopram were most effective in this age group
compared with other SSRIs [6].
Both efficacy and adverse effects of SSRIs in younger
patients are ongoing areas of investigation. Modeling the
effects of juvenile SSRI treatment in rats [7,8] and mice
[9] demonstrated that between postnatal (P) day 21 and
35, there are differences in drug response [10]. However,
data on SSRI exposure during adolescence in rodents
has received less attention. There are two issues con-
cerning age-related effects of SSRI exposure: (1) efficacy
and (2) long-term or adverse effects.
In one experiment, male Wistar rats were treated with
15 mg/kg of paroxetine or 30 mg/kg of fluvoxamine by
gavage from postnatal days (P) 33-62 and tested 20-21
days later for sexual behavior, 23-24 days later in the ele-
vated plus-maze (EPM), 31 days later for acoustic startle
response (ASR) with prepulse inhibition (PPI), 35-36
days later in the Porsolt forced swim test (FST), and 56
days later in an elevated T-maze [11]. Both drugs
decreased time in open arms in the EPM, but in an ele-
vated T-maze in which 5 trials were given from a closed
stem to open arms, only on trial-2 did fluvoxamine sig-
nificantly increase time to enter an open arm. On the
converse arrangement (open to closed entry), no change
was seen. No change in ASR/PPI, immobility in the FST,
or in 8-OH-DPAT-induced 5-HT1A-related behaviors
was observed (lower lip retraction or sexual facilitation).
A reduction in ejaculatory frequency was found in the
drug groups during the third week of testing, but not
during weeks 1 and 2; no differences were found for eja-
culatory latency, mount frequency, or intromissions.
More recently the effects of fluoxetine were tested in
adolescent mice [12]. C57BL/6J and BALB/cJ male mice
were treated with fluoxetine in drinking water at con-
centrations of 80 or 160 mg/L on P21-42 or P56-84
with testing 30 days later on open-field, EPM, cued con-
ditioned fear and extinction, the FST, plasma corticos-
terone, and brain 5-HT and 5-HIAA. The lower dose
was calculated to be 9-10 mg/kg/day and the higher
dose 17-18 mg/kg/day. In neither strain, at neither dose
did significant effects emerge [12]. No changes in 5-HT,
5-HIAA, or corticosterone after the FST were seen.
Hence, the evidence is divided as to whether SSRI
exposure during adolescent brain development has
immediate and/or untoward lasting effects. The purpose
of the present experiment was to test whether
adolescent exposure to two widely used SSRIs (fluoxe-
tine and paroxetine) has immediate or long-term effects.
The previous experiments tested animals 21-56 or 30
days after drug exposure. To determine if effects occur
while on-drug and persist after drug cessation, we trea-
ted two cohorts of rats identically and tested one cohort
while on-drug and the other after drug discontinuation.
We used the Porsolt FST because it is related to
depression, the therapeutic target of these drugs. We
assessed sensorimotor gating using ASR/PPI because
this is a widely used marker for abnormalities in neu-
ropsychiatric disorders [13-16]. We used the EPM to
determine whether SSRIs cause changes in anxiety, and
we assessed plasma corticosterone after FST to deter-
mine if stress reactivity was altered by SSRI exposure.
There are many SSRIs. We focused on paroxetine
because it showed residual effects previously [11] and
fluoxetine because it is FDA approved for use in juvenile
and adolescent patients (6-18 years of age). We used the
same treatment days as de Jong et al. [11], i.e., P33-62,
an age range from puberty to young adulthood in rats.
One cohort was tested while on-drug after 25 days of
prior treatment (tested on P57-62) and the other cohort
off-drug (P122-127; 60 days post-treatment). We tested
doses from the literature showing effects after adoles-
cent exposure [11,12]. A third dose of paroxetine was
included to match the dose used by de Jong et al. [11].
Methods and materials
Animals and treatments
Male (251-275 g) and female (151-175 g) Sprague-Daw-
ley CD, IGS rats (Charles River, Raleigh, NC) were bred
in house after one to four weeks of acclimation to the
vivarium and offspring were the subjects for these
experiments. Evidence of pregnancy was designated as
E0 (embryonic day zero) and most females delivered on
E22. Birth was designated P0 and litters were culled to 6
males and 2 females on P1. Litters not having a suffi-
cient number of males were not included in the experi-
ment. At total of 41 litters were enrolled in the
protocol. All litters were treated identically, the only dif-
ference being that offspring from 21 litters were tested
while on drug (Group A testing began on P57) and off-
spring from the remaining 20 litters were tested begin-
ning 60 days after the last day of treatment (Group B
testing began on P122). Only males were tested, there-
fore, 6 animals/litter × 41 litters = 246 animals in the
experiment. Animals were maintained in polycarbonate
shoebox cages (46 × 24 × 20 cm) on a 14 h light/10 h
dark cycle (lights on at 600 h) with food (NIH-07 diet)
and water available ad lib in a vivarium maintained at
21 ± 1°C with 50 ± 10% humidity and accredited by the
Association for the Accreditation and Assessment of
Laboratory Animal Care (AAALAC). The research
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protocol was approved by the Cincinnati Children’s
Research Foundation’s Institutional Animal Care and
Use Committee. Offspring were separated from their
dams on P28 and housed 2 per cage for the remainder
of the experiment. Each cage contained a semicircular
stainless steel enclosure (17.8 cm long with the open
side 18.4 cm across and 10.2 cm high with the open
side down made of 16-gauge stainless steel) as an addi-
tional environmental enrichment.
Drugs and doses
Animals were weighed daily during treatment and weekly
thereafter. All animals received a daily gavage from P33-62
of 5 ml/kg body weight of USP grade water alone or water
containing one of the drugs. Drugs were obtained as
hydrochloride salts and all doses are expressed as the salt
form. The treatment groups were as follows: Control
(water), Flu3 (Fluoxetine 3 mg/kg), Flu10 (fluoxetine 10
mg/kg), Par 3 (paroxetine 3 mg/kg), Par10 (paroxetine 10
mg/kg), and Par 17 (paroxetine 17.04; this dose matched
the dose of paroxetine reported previously [11] as 15 mg/
kg expressed as the freebase). Fluoxetine HCl was obtained
from Eli Lilly and Company (Indianapolis, IN) and paroxe-
tine HCl was obtained from Suzhou ChonTech Pharma-
Chem Technology Company (Suzhou, China).
Drug stability and potency
Drugs were mixed weekly in 5 ml of water in the appro-
priate concentrations to deliver the specified doses. In
order to verify drug concentrations for each solution, a
set of drug solutions at each concentration was made
and sent to ABC Laboratories (Columbia, MO) for veri-
fication. In order to ensure stability of these solutions a
set of the highest concentration solution of each drug
was made and analyzed at 0, 3, or 7 days post-mixing by
ABC Laboratories. Finally, drug potency was assayed on
both drug stocks at the end of the experiment to ensure
that no degradation had occurred by sending an aliquot
of each drug to ABC Laboratories for analysis.
Drug concentrations were analyzed via high perfor-
mance liquid chromatography with ultraviolet detection
(HPLC-UV) at 227 nm. Samples were injected onto a
Zorbas SB-Phenyl reversed phase column (250 × 4.6
mm, 5 μm). The HPLC system was an Agilent HP 1100.
The mobile phase was 50% acetonitrile, 50% 0.1% TFA
aqueous. The flow rate was 1.0 ml/min, attenuation was
1000 mAU at ambient temperature with a column tem-
perature of 30°C. Sample size was 20 μl and run time
was 10 min. Final drug concentrations were calculated
from a standard curve in the linear range.
Behavioral testing and sample collection
Group A and B animals were tested in the same beha-
vioral tasks but at different ages. Group A had 21 litters
and Group B had 20 litters resulting N/group for each
test ranging from 19-21/test for Group A and 16-20/test
for Group B. The tests were (in order): EPM, ASR/PPI,
and the Porsolt FST (immediately followed by decapita-
tion and blood collection for determination of plasma
corticosterone). There were 2 days of separation
between each test. Group A was tested in the EPM on
P57, ASR/PPI on P59, and FST on P61-62. Group B was
tested in the EPM on P122, ASR/PPI on P124, and FST
on P126-127. For Group A, all tests while on-drug were
given not less than 1 h and not more than 4 h after
each daily dose.
Elevated plus maze
This test was conducted on a single day. The apparatus
was constructed of high-density, black polyethylene
polymer. Each arm was 10 × 50 cm, with two opposing
open arms and two perpendicular opposing arms with
high side walls (closed arms). The walls were 50 cm
high in the closed arms and the open arms had 0.6 cm
curbs on the edges to prevent falls. The apparatus was
mounted 50 cm above the floor. During testing the
room was lit by a single dimmed halogen lamp (aimed
upward to reflect off the ceiling). Each animal was tested
for 5 min and movements were recorded on a DVD
recorder using an overhead camera. Behavior was later
played back and scored by an observer blind to treat-
ment group for time-in-open, number of open entries,
latency to first open entry, and head dips. An arm was
scored as entered if the animal’s head and two front feet
crossed a boundary line between the center region and
that arm.
Acoustic startle/PPI
This test was conducted on a single day. Acoustic startle
reactivity with reflex modified inhibition by prepulse sti-
mulation (ASR-PPI) was measured in four identical SR
Lab test chambers (San Diego Instruments, San Diego,
CA). Each test chamber was calibrated using the manu-
facturer’s guidelines and sensitivity was regularly
checked using a calibrated oscillation device to ensure
consistent sensitive readings. At the start of each test,
animals were placed in acrylic cylindrical tubes mounted
atop piezoelectric force transducers positioned inside
sound attenuating test chambers. Background white
noise was set at 70 dB. The test paradigm reported pre-
viously was duplicated as closely as possible [11]. Each
test session consisted of a 5 min acclimation period fol-
lowed by a 5 × 5 Latin square sequence of trials of 5
different types: no stimulus, startle signal with no pre-
pulse, startle signal with prepulse 3 dB above back-
ground (73 dB), startle signal with prepulse 5 dB above
background (75 dB), and startle signal with prepulse 10
dB above background (80 dB). Each animal received
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each trial type once in each of the 5 orders, and the
entire Latin square sequence was repeated; hence, each
animal received each trial type/order twice. Trials of the
same type were averaged together for analysis. The
intertrial intervals were 10-20 s with randomized spa-
cing. The interstimulus interval was 100 ms (measured
from prepulse onset to startle signal onset). The startle
signal was a 120 dB mixed frequency, white noise burst
that lasted for 20 ms. The recording window was 100
ms. Prepulses lasted for 20 ms. Stimulus intensity was
measured using a Quest sound level meter (SPL scale)
with the meter placed in the test chamber in the center
of the test stage with the door closed and the micro-
phone directed upward toward the ceiling-mounted
speaker. Response amplitude (Vmax = maximum voltage
change within the recording window) was recorded in
units of voltage change (mV). Test chambers were
cleaned with 70% ethanol between animals.
Porsolt forced swim test
Testing was conducted over two successive days using
the original method of Porsolt for rats [17,18]. The
apparatus consisted of four clear acrylic cylinders 19 cm
in diameter (i.d.) and 60 cm in height filled to a depth
of 30 cm (to avoid water depth concerns [19]) with
room temperature water (21-23°C). On day-1 rats were
placed in the cylinders for 15 min and on day-2 for 5
min. Each chamber was separated by black acrylic parti-
tions to prevent animals from seeing one another.
Movement was recorded using a video camera and DVD
recorder. Scoring was performed by an experimenter
blind with respect to treatment group. Immobility dura-
tion was scored on day-2 as time spent not swimming
or reaching at the walls. Occasional, minor limb move-
ments were permitted in order for the animal to main-
tain balance, brace itself against the wall, or tread water
to keep afloat so long as a coordinated multi-limb swim-
ming motion was not present. We did not use the
expanded FST method [20,21] because we were not test-
ing SSRI efficacy, but rather for toxicity.
Tissue collection
Upon the completion of the FST, animals were removed
from the water, carried to another room where they
were decapitated (< 30 s from removal from FST), and
blood collected for later plasma corticosterone
determinations.
Corticosterone assay
Blood was collected in tubes that contained EDTA (2%
in 0.05 ml). Samples were centrifuged for 15 min at 4°C,
plasma removed and stored at -80°C until assayed. Cor-
ticosterone concentrations were determined by diluting
plasma 1:10 in assay buffer and assayed in duplicate
using a commercially available EIA kit (IDS, Fountain
Hills, AZ). All determinations were made from kits ori-
ginating from the same lot.
Statistical analyses
Data for Group A and Group B animals were analyzed
separately. Data were analyzed using completely rando-
mized block analyses of variance (ANOVA) mixed linear
models (SAS Proc Mixed, SAS Institute, Cary, NC). The
Kenward-Roger adjusted degrees of freedom method
was used and can be fractional. In these analyses, litter
was the block factor. Data from the EPM and FST had
1-between-subject factor (treatment group). ASR-PPI
had 1-between-subject factor (treatment group) and 1-
within-subject factor (trial). For body weight, the
ANOVA has 1-between-subject factor (treatment group)
and 1-within-subject factor (age). Interactions were ana-
lyzed using the slice-effect ANOVA method on each
level of within-subject factors. A posteriori group com-
parisons were analyzed using the Hochberg step-up
method to control for multiple comparisons. As follow-
up we report effect size (ES) for drug treatment for each
behavior. There are no methods for calculating ES for
mixed linear ANOVA, therefore, we reanalyzed the data
using general linear model ANOVA (GLM) again with
litter as a random block factor. SAS GLM provides
three indices of ES (noncentrality, partial, and semipar-
tial correlation ratios). These reanalyses produced results
nearly identical to those obtained from Mixed model
analyses, thereby validating the use of ES values from
GLM ANOVA models. We then took the semipartial
correlation ratios (eta-square) and converted them to
Cohen’s f (similar to Cohen’s d, except for ANOVAs
rather than for t-a test) and followed Cohen’s categori-
zation scheme (small ES are around 0.2, medium around
0.5, and large ≥ 0.8 [22]. Significance was taken as p ≤
0.05 and data are presented as least square mean ±
SEM.
Results
Drug Concentrations and Stability
Drug solutions of both compounds were prepared and
sent to ABC Laboratories for analytical chemistry to
determine drug concentrations by HPLC analysis (Meth-
ods; M-1736-000 and USP 30 Paroxetine HCl). Each
sample was analyzed in triplicate. The first set of sam-
ples was taken from prepared test solutions for concen-
tration verification. Mean concentrations of the test
solutions were within 3% of target concentrations.
Stability Assessment: Fluoxetine hydrochloride is
known to be stable in solution ≥ 7 days but to deter-
mine the stability of paroxetine we tested it at the low
and high concentrations at three time points: immedi-
ately after preparation and at 3 and 7 days. The
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paroxetine solutions showed no decrease in active drug
content over the 7-day period.
End of Study Drug Purity: After the completion of the
experiment, crystalline samples of both drugs were sent
to ABC Laboratories to determine drug purity. Both
paroxetine HCl and fluoxetine HCl were unchanged
(mean percent potency of 101%).
General Characteristics
There were no deaths; 100% of the animals enrolled in
the experiment survived and were tested. Group sizes
varied slightly from the design because of experimenter
error or equipment malfunction. The exact N for each
test is provided in the figure captions.
Body weight data were analyzed by age. Once off-
spring were assigned to treatment groups, their body
weights from P1-28 were analyzed to ensure that no
preexisting differences occurred. This analysis showed
no differences as a function of later assignment to the
groups (F(5,200) = 1.09, p > 0.36). The effect of age was
significant (F(4,960) = 23327.9, p < 0.0001),
demonstrating time-dependent growth. The group ×
week effect was not significant (F(20,960) = 0.50, p >
0.96).
Body weights during drug treatment (P33-62) were
analyzed with Groups A and B combined. There was a
significant effect of treatment (F(5,227) = 4.84, p =
0.0003), day (F(29,6922) = 1481.86, p < 0.0001), and
treatment × day (F(145,6931) = 1.49, p = 0.0001). Slice-
effect ANOVAs on each day showed no treatment
effects on P33-43, however significant effects were
obtained on days P44-62. Since there were no significant
group differences before P44, only the P44-62 body
weight data are illustrated in Figure 1. Body weights on
the last day of treatment (P62) were analyzed separately
for Groups A and B and are shown in Figure 2. As can
be seen, for Group A, the Flu10 and Par 17 groups
weighed less than Control. For Group B, only the Flu10
group weighed less than Control. The Par17 for Group
B was not significantly different from Control (p = 0.12).
Group A animals completed testing by P62, hence
there are no body weight data for this group after P62.
Figure 1 Body weights during treatment: Data represent least square mean (± SEM) body weights (g) on days on which significant
group differences were obtained. Treatment was from P33-62; significant group differences occurred on P44-62. Groups A and B are
combined. Group sizes: Group A = 21, Group B = 20.
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For Group B, body weights were recorded on P63 and
weekly thereafter until the end of testing on P126. In
order to map body weight recovery after the end of
treatment, data for the first two weeks after the end of
treatment (P63-77) were analyzed separately. There was
no significant treatment main effect (F(5,95) = 1.94, p <
0.10). The day/week factor in the analysis was significant
(F(2,228) = 4256.37 = p < 0.0001), indicating time-
dependent growth, and there was a significant treatment
× week interaction (F(10,228) = 9.59, p < 0.0001). Slice-
effect ANOVAs on each week showed differences on
P63 (p < 0.01) but not on P70 or P77, indicating that
recovery was rapid (< 1 week). This pattern is illustrated
in Figure 3. As can be seen, only the Flu10 group
weighed significantly less on P63 and no differences
remained on P70, P77, or thereafter (i.e., between P84-
126 (not shown)).
Elevated plus maze
For Group A there were no significant differences in
time spent in the open arms, number of open arm
entries, or latency to first open arm entry (Figure 4A-C,
respectively). A significant treatment group effect was
found on number of head dips (F(5,95) = 2.74, p <
0.03). Post hoc group comparisons showed that the
Par17 group had fewer head dips than Controls (Figure
4D). No other group comparisons were significant. ES
for time in open arms were = 0.15 (small), for arm
entries = 0.13 (small), for latency = 0.12 (small), and for
head dips = 0.27 (small).
For Group B there were no significant differences in
time spent in the open arms, number of open arm
entries, latency to first open arm entry, or head dips
(Figure 4E-H, respectively). ES for time in open arms =
0.18 (small), for arm entries = 0.22 (small), for latency =
0.16 (small), and for head dips = 0.09 (small).
Acoustic Startle/PPI
ASR-PPI data were analyzed two ways: (a) by prepulse
intensity, and (b) using the 0 prepulse response ampli-
tude as a covariate by ANCOVA in order to assess PPI
after controlling for any possible differences in basal
startle reactivity.
For the Group A startle response ANOVA, the treat-
ment group main effect was not significant but showed
a trend (F(5,98.2) = 1.95, p < 0.10). There was no signifi-
cant treatment × prepulse interaction. Prepulse intensity
was significant (F(3,354) = 100.32, p < 0.0001) showing
that prepulse inhibition of ASR was obtained. In the
ANCOVA analysis, no significant treatment main effect
was seen (F(5,98) = 1.86, p = 0.11). The treatment × PPI
interaction was not significant. The prepulse main effect
was significant (F(2,236) = 68.01, p < 0.0001). The data
are shown in Figure 5(top panel). ES for Group A =
0.27 (small).
An inspection of Figure 5 taken together with the
treatment main effect trend (p < 0.10) led us to con-
duct two follow-up analyses. In both analyses we com-
bined the two Flu groups ’ data and the three Par
groups’ data into single Flu and Par groups. In the first
follow-up analysis, all prepulse trials were included in
a treatment × prepulse ANOVA. The treatment main
effect (F(2,39) = 7.13, p < 0.003) and prepulse main
effect (F(3,177) = 88.43, p < 0.0001) were both signifi-
cant and the treatment × prepulse interaction showed
a trend (F(6,177) = 1.89, p < 0.09). Post hoc group
comparisons (averaged across prepulse intensities)
showed that both the Flu and Par groups differed from
Control (mean ± SEM: Control: 149.0 ± 23.5; Flu:
Figure 3 Body weights: Least square Mean (± SEM) body
weights for Group B during the two weeks after the end of
treatment. Significant group differences occurred on P63; only the
Flu10 group weighed significantly less than Controls. From P70 to
the end of the experiment, there were no significant treatment
group differences. *p < 0.05.
Figure 2 Body weights: Least square Mean (± SEM) body
weights on the last day of treatment (P62). Group A and B are
shown separately. There were 21 litters in Group A and 20 litters in
Group B. **p < 0.01 vs. Control.
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Figure 4 Elevated plus maze: Data shown are least square means (± SEM) on the EPM during the 5 min test session. A,E: time (s) spent
in open arms; B,F: number of open arm entries; C,G: latency to first open arm entry; and D,H: number of open arm head dips. Group A was
tested on P57 and Group B on P122. Group sizes for Group A: Number of litters tested = 21; data are based on the following number of
subjects/group: Control = 20, Flu3 = 20, Flu10 = 20, Par3 = 20, Par10 = 20, Par17 = 20. One litter’s data were missing because of a DVD playback
defect. For Group B: Number of litters tested = 20; data are based on the following number of subjects/group: Control = 16, Flu3 = 16, Flu10 =
16, Par3 = 16, Par10 = 16, Par17 = 16. Data were unrecoverable from 4 litters whose recorded data tracks would not playback from the DVD.
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224.4 ± 23.0; Par: 252.7 ± 23.0). This facilitated startle
effect was most pronounced on the no-prepulse trials,
therefore, the second follow-up ANOVA was with the
combined dose groups but only on the no-prepulse
trials. ES for the latter = 0.44 (medium). With no pre-
pulses in the analysis, the ANOVA was a simple one-
way analysis with 3 groups. The treatment effect was
significant (F(2,39) = 6.55, p < 0.004). This effect is
shown in Figure 6(left panel). Post hoc group compar-
isons revealed that both drug groups showed signifi-
cantly increased startle amplitude compared with the
Control group. ES for the latter = 0.42 (medium).
For Group B the treatment × prepulse ANOVA
showed no significant main effect of treatment group or
treatment × prepulse intensity interactions. Prepulse
intensity was significant (F(3,339) = 92.60, p < 0.0001)
showing that ASR was significantly modified by the PPI
procedure (Figure 5, bottom panel). The ANCOVA
analysis showed a similar outcome, no significant treat-
ment main effect or treatment × prepulse interaction.
The prepulse main effect was significant (F(2,226) =
48.20, p < 0.0001). ES = 0.18 (small).
As for Group A, follow-up analyses with dose-levels of
each group combined were conducted for Group B, and
Figure 5 Acoustic startle/PPI: Least square Mean (± SEM) startle amplitude (Vmax) measured in units of voltage change (mV). Group A
was tested on P59 and Group B on P124. No treatment group effects were obtained for either Group A or B, nor any treatment × prepulse
interactions. Prepulse was significant and showed that the greater the prepulse intensity the greater the inhibition of the startle response.
Number of litters in Group A = 21. Progeny group sizes for Group A: Control = 20, Flu3 = 21, Flu10 = 21, Par3 = 20, Par10 = 21, Par17 = 21. For
Group A, 1 Control and 1 Par3 animal had missing data because they were tested with the incorrect startle program. Number of litters for Group
B = 20. Progeny group sizes for Group B: Control = 20, Flu3 = 20, Flu10 = 20, Par3 = 19, Par10 = 20, Par17 = 20. For Group B, 1 Par3 animal’s
data were missing because the test chamber power was not activated.
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there was no significant treatment main effect or treat-
ment × prepulse interaction. ES = 0.06 (small). Prepulse
was significant (F3,171) = 72.39, p < 0.0001). An addi-
tional analysis performed on the no-prepulse trials by
one-way ANOVA showed no significant treatment effect
(Figure 6, right panel). ES = 0.06 (small).
Porsolt FST
For Group A, there were no significant treatment group
effects found on immobility time (Figure 7, top panel)
or latency to immobility (not shown) in the FST. ES =
0.20 (small).
Similarly, for Group B there were no significant effects
of treatment group found on immobility time (Figure 7,
bottom panel) or latency to immobility (not shown) in
the FST. ES = 0.21 (small).
Corticosterone
For Group A, all groups showed high corticosterone
levels at the end of the 5 min FST compared with typi-
cal basal levels (~50 ng/ml) however there were no
treatment differences among the groups (Figure 8, left
panel).
For Group B, again all groups showed increased corti-
costerone levels in response to the stress at the end of
the FST but there were no significant effects of treat-
ment obtained (Figure 8, right panel).
Discussion
Fluoxetine, paroxetine, and many other SSRIs have pro-
ven to be efficacious for the treatment of adults with
depression, premenstrual syndrome, obsessive compul-
sive behavior, panic disorder, generalized anxiety
disorder, social anxiety disorder, and post-traumatic
stress disorder [1-3]. These drugs have been found to be
safer and have fewer side-effects than tricyclic antide-
pressants. SSRIs have also been used in children and
adolescents, and fluoxetine is approved for use in those
6-18 years of age. In children whose nervous system is
still developing, there are concerns about the long-term
effects of these drugs.
In a recent preclinical experiment examining paroxe-
tine and fluvoxamine, it was reported that these drugs
reduced time-in-open in an EPM [11]. Decreased time
in open in the EPM is the most widely accepted index
for this test of increased anxiety-like behavior [23]. In
the experiment by deJong et al. [11] this change
occurred for both drugs 20-30 days after the end of
treatment. No change was seen in the number of zone
crossings. These authors also tested the animals in an
Figure 6 Acoustic startle for the no-prepulse trials: Data are
group least square mean (± SEM) startle amplitude (Vmax)
measured in units of voltage change (mV). Group A was tested
on P59 and Group B on P124 as for Figure 5. Group sizes are as in
Figure 5. *p < 0.05, **p < 0.01 compared with Control.
Figure 7 Porsolt forced swim test: Least square Mean (± SEM)
immobility time on the test trial (day-2; out of 300 s). Animals
received a 15 min training trial 24 h previously. Group A was tested
on P61-62 and Group B on P126-127. Group sizes: Number of litters
tested in Group A = 21; data are based on the following number of
subjects/group: Control = 19, Flu3 = 21, Flu10 = 20, Par3 = 21,
Par10 = 21, Par17 = 21. Two Control and one Flu10 animal had
missing data tracks on the DVD because of playback issues. Number
of litters tested in Group B = 20; data are based on the following
number of subjects/group: Control = 19, Flu3 = 19, Flu10 = 20, Par3
= 20, Par10 = 20, Par17 = 20. Tracks for two Control and one Flu3
animal would not playback on the DVD.
Vorhees et al. Behavioral and Brain Functions 2011, 7:41
http://www.behavioralandbrainfunctions.com/content/7/1/41
Page 9 of 13
elevated T-maze (the EPM was used with one arm
blocked). Out of 5 trials for time to enter an open arm
after being placed in a closed arm, both SSRI-treated
groups entered an open arm faster on trial-2 compared
with controls but not on trial-1 or 3-5. When the situa-
tion was reversed and they were given an additional trial
by being placed in an open arm and timed for entry
into a closed arm, no differences were found. No differ-
ences in ASR/PPI were obtained nor were changes
obtained on immobility time in the FST.
We sought to further test the effects of adolescent
exposure to SSRIs and followed many of the design fea-
tures used previously [11], except using more dose levels
of each drug and including separate groups of animals,
half tested while on-drug (Group A) and half tested off-
drug (Group B; 60 days post-treatment). If long-term
effects of SSRI treatment were obtained, it would poten-
tially represent a concern for the safety of the drugs.
Both drugs produced body weight reductions at the
highest doses tested by P44, i.e., after 12 days of treat-
ment, and these reductions remained through the end
of treatment (P62). But the effects showed recovery to
non-significant differences one week post-treatment.
Behaviorally, no treatment-related effects on the EPM
were obtained on the principal measure of anxiety, i.e.,
time-in-open. In addition, no differences were found for
number of zone crossings or latency to first open arm
entry. The Group A Par17 animals showed a significant
reduction in head-dips, an effect seen in no other group,
however this effect was not seen in Group B when
tested 60 days after drug cessation. deJong et al. [11] did
not report head-dips, therefore, it is not possible to
make a direct comparison on this variable, however, a
reduction in head-dips is generally interpreted as an
increase in anxiety [24], although it is an index of anxi-
ety that is secondary to time-in-open and therefore pro-
vides less persuasive evidence of a significant change in
anxiety. However, this effect would be consistent with
the finding of deJong et al. [11]. A recent study showed
that rats treated from P25-49 with 12 mg/kg of fluoxe-
tine had reduced time-in-open in the EPM [25] 7 days
post-treatment, a finding consistent with reduced head-
dips that we found while animals were on drug. It is
unclear why adolescent exposed rats and mice show
greater inconsistency in EPM responses to SSRIs than
adult rodents. Some of it may be related to the different
Figure 8 Corticosterone: Mean (± SEM) plasma corticosterone levels obtained immediately after the end of the FST. No differences
were observed for either drug compared with Control. Group sizes: Number of litters tested in Group A = 21; data are based on the following
number of subjects/group: Control = 21, Flu3 = 21, Flu10 = 21, Par3 = 21, Par10 = 21, Par17 = 21. Number of litters tested in Group B = 20; data
are based on the following number of subjects/group: Control = 19, Flu3 = 19, Flu10 = 19, Par3 = 19, Par10 = 19, Par17 = 19.
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exposure ages as there is no consistent definition of
adolescence in rodents. Doses and routes of drug
administration as well as duration of treatment and end
of treat to test interval vary widely across studies,
increasing the difficulty of discerning patterns.
Neither we nor deJong et al. (2006) found any effect
on the FST test of swimming despair [17,18] and this
finding is different than that reported by Homberg et al.
[25] but they treated rats earlier (P25-46); moreover,
they found no differences in rats treated at a later age.
Other studies have found opposite or paradoxical effects
of adolescent exposure to fluoxetine in mice, but only in
one of the two strains tested [26]. To the extent that the
FST is a valid preclinical test of depression, the data do
not suggest that adolescent exposure to fluoxetine or
paroxetine result in long-term changes in immobility.
This is consistent with a newer report of chronic fluoxe-
tine treatment in mice from P14-42 showing no FST
effects [26] and the data cited above [12]. We scored
the FST for immobility time as originally described by
Porsolt et al. [17,18]. We did not score the test using
the recently suggested indices of active swimming and
wall climbing [20]. While we cannot rule-out the possi-
bility that these additional indices might have uncovered
other effects, we did not include them because our
interest was not differentiating among different classes
of SSRIs, which was the reason these measures were
introduced, but rather whether immobility was a long-
term consequence of drug exposure after adolescent
treatment.
Others have administered SSRIs by osmotic pump in
order to maintain plasma concentrations in animals
within the same range as human therapeutic concentra-
tions [27,28]. The intent of these studies was different
than ours. These studies were designed to assess the
molecular targets of SSRIs. For this purpose maintaining
a constant drug concentration is desirable but this goal
was not necessary for our purposes of determining if
these drugs have persistent long-term effects long after
cessation.
deJong et al. [11] reported no changes in ASR/PPI.
We replicated their parameters and in agreement,
observed no changes in ASR or PPI from either drug 60
days post-treatment. However, while on-drug, we saw a
trend toward ASR facilitation that did not interact with
PPI. To further explore the data, we conducted follow-
up analyses by combining the two fluoxetine groups
into one pooled group by averaging the data for the
fluoxetine animals in each litter together to create a sin-
gle, merged group. We did the same for the paroxetine,
merging the data from all three dose levels together
among littermates to create a single paroxetine group.
Two follow-up analyses were performed. These were: (1)
with all prepulse trials included and (2) with no-
prepulse trials included, i.e., only the unmodified, basic
ASR trials. Both analyses resulted in the same finding:
the pooled fluoxetine and pooled paroxetine groups
exhibited increased ASR amplitude compared with Con-
trols. By contrast, when Group B ASR-PPI data were
analyzed the same way, no residual effect or trend
toward an effect was observed. This is in contrast to a
study that found that P24-46 fluoxetine reduced ASR at
a higher dose than we used (12 mg/kg), but similar to
our data, found no effects at later ages [25].
The present data should be viewed within the limita-
tions of the study. As in the deJong et al. [11] and Nor-
cross et al. [12] studies, we tested only males. It may be
worthwhile to test females as many drugs exhibit sexu-
ally dimorphic responses. It is also worth considering
that future experiments might test a broader range of
doses in order to more thoroughly test for possible
adverse effects. Finally, other behavioral tests might be
worth considering; Norcross et al. [12] also included
open-field and cued fear conditioning with extinction,
but even more tests might be considered such as fear-
induced acoustic startle facilitation. There are many
tests of anxiety, conditioned fear, sensorimotor gating,
and depression, of which only a subset were used here
or in the other studies cited that tested for residual
effects. A more extensive battery of tests might reveal
effects not detected herein.
Overall, the data show that for the doses of fluoxetine
and paroxetine tested by an oral route during adolescent
to early adult brain development (operationally defined
as P33-62), caused minor and only transient reductions
in body weight gain, a small but significant ASR facilita-
tion during treatment that did not remain 60 days post-
treatment, and a high-dose only (Par17) reduction in
EPM head-dips while on-drug but not off-drug. The
findings, when considered in terms of the power to
detect differences in the present experimental design (≥
20 animals per group), multiple dose levels, use of a
within-litter design that improves subject matching, and
inclusion of both on- and off-drug cohorts, suggest that
there is no signal of adverse effects present in the data
that might raise concern over the long-term safety of
the drugs when treatment is during an interval spanning
adolescent brain development in rats, in agreement with
previous findings in mice [12]. It was recently reported
that fluoxetine given by continuous infusion via mini-
pumps from P14-42 results in anxiogenic effects in mice
while on-drug on tests of novelty-induced hypophagia in
Swiss-Webster (SW) and C57BL/6 Charles River (B6)
mice, however there were no effects in the EPM in the
SW strain and reduced time-in-open in the B6 strain
but no effects on open-field center time or FST in either
strain. These effects disappeared off-drug [26] which is
entirely consistent with the present findings. Thus, while
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SSRIs induce relatively reliable effects on-drug in adult
rodents, their effects from adolescent exposure are less
consistent. Our data are consistent in that we saw only
small effects while on drug and no long-term effects
long after drug discontinuation. The latter provides
some evidence that these drugs are not neurotoxic when
given during adolescent stages of brain development at
least on the behavioral indices used here.
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